NC startup raises $17.5M as it explores alternative to the EpiPen
A Triangle pharmaceutical startup has raked in $17.5 million to fund commercialization of a nasal-spray that the company thinks could serve as an alternative to the EpiPen.
A Triangle pharmaceutical startup has raked in $17.5 million to fund commercialization of a nasal-spray that the company thinks could serve as an alternative to the EpiPen.